Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neuro-Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GPR34 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPR34 Lentivirus Premade Particles Full-length human GPR34 sequence for stable cell line generation. Native 7-transmembrane conformation preserved. High Titer, Sequence Verified. |
View GPR34 Products |
| Gene Delivery | GPR34 Promise-ORF / Lentivirus Expression-ready particles for transient transfection or stable pool generation in HEK293/CHO. |
View GPR34 Products |
| Benchmark Ab | Anti-GPR34 Clinical Benchmark Antibody Recombinant positive control derived from clinical-stage leads for flow cytometry and binding validation. |
View GPR34 Products |
| Validator | GPR34 siRNA Set Target-specific knockdown pool for functional assay validation and specificity screening. |
View GPR34 Products |
| Related Target A | GPR174 Co-receptor for Lysophosphatidylserine (LysoPS). Crucial for evaluating pathway-wide selectivity and synergistic immune-checkpoint blockade. |
View GPR174 Products |
| Related Target B | P2RY12 Structurally related purinergic GPCR. Essential for counter-screening to ensure off-target safety and microglia-specific targeting. |
View P2RY12 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-Pass Membrane Conformation Loss | Lentivirus-driven full-length expression ensures native folding in live host cells, eliminating VLP-associated instability. |
| Subfamily Off-Target Cross-Reactivity | Ortholog and homolog panel targets (GPR174, P2RY12) available for rigorous counter-screening. |
| Lack of Reliable Controls | Sequence-verified clinical benchmark antibodies included for assay standardization. |
| False Positive Knockdown Signals | Sequence-validated siRNA sets included to confirm target-specific phenotypic changes. |
Live GPR34 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPR34 therapeutics is intensifying, with major players shifting focus from traditional oncology targets to myeloid-derived suppressor cell (MDSC) and microglia modulators. As first-generation small molecule antagonists and monoclonal antibodies reach pre-clinical and early clinical milestones, the next wave of R&D is targeting GPR34-mediated lysophosphatidylserine (LysoPS) signaling to reverse the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Biotech Pioneers, Academic Consortia | Solid Tumors, Lymphoma | Flow Cytometry & Binding Assays (Need native-conformation cell lines) |
| Small Molecule Antagonist | Global Pharma, Oncology Startups | Neuro-oncology, Autoimmune Diseases | Functional GPCR Activation (Need high-titer lentivirus for cAMP/Calcium flux) |
| Bispecific / Multi-specific | Next-Gen Immunotherapy Firms | Refractory Microenvironment | Selectivity Screening (Need GPR174 / P2RY12 homolog panels) |